ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Inclusion Criteria: * Provide written informed consent. * Primary subfoveal choroidal neovascularization (CNV) secondary to AMD, including predominantly classic, minimally classic or occult lesions, in the study eye. * New diagnosis of wet AMD or evidence of recent disease progression within the last 3 months in study eye. * Evidence of subretinal fluid or retinal cystic changes with a CSFT of \> 340 μm using a Spectralis SD-OCT (Heidelberg Engineering) imaging system. * Best-corrected visual acuity (BCVA) of Snellen equivalent 20/200 or better in the non-study eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Previously administered therapy, approved or investigational, for wet AMD in the study eye. * Any current or history of macular or retinal disease in the stuy eye other than wet AMD. * Lasik or cataract surgery within the last 3 months in the study eye or expected to have cataract removal surgery during the study. * Uncontrolled or advanced glaucoma in the study eye. * Use of systemic or topical ocular corticosteroids. * History of a medical condition that, in the opinion of the Investigator, would preclude scheduled visits, completion of the study, or safe administration of study medication. * Abnormal or unsuitable laboratory results at Screening visit. * Lactating or pregnant. Women of childbearing potential must use adequate birth control for the duration of the study. * Other protocol-defined exclusion criteria may apply.